TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Conduit Pharmaceuticals ( (CDT) ) is now available.
On October 8, 2025, CDT Equity Inc. filed a certificate of amendment to effectuate a 1-for-8 reverse stock split of its common stock, which was approved by stockholders at a special meeting on May 5, 2025. The reverse stock split will become effective on October 10, 2025, and the common stock will begin trading on a split-adjusted basis on Nasdaq on October 13, 2025, under the ticker symbol ‘CDT’. This move is expected to potentially increase the funds available for the company’s strategic initiatives.
More about Conduit Pharmaceuticals
CDT Equity Inc. is a data-driven biopharmaceutical development company that focuses on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments, aiming to create shareholder value through licensing, strategic M&A, and positioning itself as a platform for transformative innovation.
Average Trading Volume: 4,480,279
Technical Sentiment Signal: Sell
Current Market Cap: $2.35M
For a thorough assessment of CDT stock, go to TipRanks’ Stock Analysis page.